138 related articles for article (PubMed ID: 10407985)
1. [Colony stimulating factors in polychemotherapy of testicular tumors. A comparison between G-CSF and GM-CSF].
Will R; Hofmockel G; Langer W; Frohmüller H
Urologe A; 1999 May; 38(3):258-63. PubMed ID: 10407985
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 5 vs 10 micrograms/kg per day of GM-CSF following dose-intensified chemotherapy with cisplatin, etoposide, and ifosfamide in patients with advanced testicular cancer.
Bokemeyer C; Schmoll HJ; Metzner B; Beyer J; Illiger HJ; Kneba M; Ostermann H; Kynast B; Räth U; Poliwoda H
Ann Hematol; 1993 Aug; 67(2):75-9. PubMed ID: 8347733
[TBL] [Abstract][Full Text] [Related]
3. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin/etoposide/ifosfamide stepwise dose escalation with concomitant granulocyte/macrophage-colony-stimulating factor for patients with far-advanced testicular carcinoma.
Harstrick A; Schmoll HJ; Bokemeyer C; Metzner B; Illiger HJ; Berdel W; Ostermann H; Manegold C; Räth U; Siegert W
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S198-202. PubMed ID: 1665492
[TBL] [Abstract][Full Text] [Related]
5. Placebo controlled phase I/II study of subcutaneous GM-CSF in patients with germ cell tumors undergoing chemotherapy.
Jost LM; Pichert G; Stahel RA
Ann Oncol; 1990 Nov; 1(6):439-42. PubMed ID: 1707298
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of filgrastim vs. sequential filgrastim and molgramostim after dose-intensified carboplatin, cyclophosphamide, and etoposide: a phase I pilot study.
Recchia F; De Filippis S; Torchio P; Rea S; Gulino A; Quaglino D; Frati L
Am J Clin Oncol; 1997 Apr; 20(2):209-14. PubMed ID: 9124202
[TBL] [Abstract][Full Text] [Related]
7. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin.
Brugger W; Birken R; Bertz H; Hecht T; Pressler K; Frisch J; Schulz G; Mertelsmann R; Kanz L
Br J Haematol; 1993 Jul; 84(3):402-7. PubMed ID: 7692928
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic growth factors and treatment of testicular cancer: biological interactions, routine use and dose-intensive chemotherapy.
Bokemeyer C; Kuczyk MA; Köhne H; Einsele H; Kynast B; Schmoll HJ
Ann Hematol; 1996 Jan; 72(1):1-9. PubMed ID: 8605273
[TBL] [Abstract][Full Text] [Related]
9. Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin.
Brugger W; Frisch J; Schulz G; Pressler K; Mertelsmann R; Kanz L
J Clin Oncol; 1992 Sep; 10(9):1452-9. PubMed ID: 1517788
[TBL] [Abstract][Full Text] [Related]
10. Double-cycle high-dose chemotherapy with peripheral blood stem cells and hematopoietic growth factor support in patients with advanced solid tumor. A pilot study by the Hong Kong Biotherapy Group.
Yeung AW; Pang YK; Tsang YC; Wong SW
Cancer; 1994 Apr; 73(7):1960-70. PubMed ID: 7511042
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte-macrophage colony-stimulating factor in neutropenic children with malignancies.
Lydaki E; Bolonaki E; Stiakaki E; Dimitriou H; Kalmantis T; Kalmanti M
Pediatr Hematol Oncol; 1995; 12(6):551-8. PubMed ID: 8589000
[TBL] [Abstract][Full Text] [Related]
12. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.
Fosså SD; Kaye SB; Mead GM; Cullen M; de Wit R; Bodrogi I; van Groeningen CJ; De Mulder PH; Stenning S; Lallemand E; De Prijck L; Collette L
J Clin Oncol; 1998 Feb; 16(2):716-24. PubMed ID: 9469362
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM-CSF.
Ford PA; Arbuck SG; Minniti C; Miller LL; DeMaria D; O'Dwyer PJ
Eur J Cancer; 1996 Apr; 32A(4):631-5. PubMed ID: 8695266
[TBL] [Abstract][Full Text] [Related]
14. Granulocyte-macrophage colony-stimulating factor given before dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP).
Holdsworth MT; Roon R; Ferguson J; Martinez L; Stidley CA; Neidhart JA
Biotechnol Ther; 1993; 4(3-4):183-95. PubMed ID: 8292969
[TBL] [Abstract][Full Text] [Related]
15. Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support.
de Wit R; Verweij J; Bontenbal M; Kruit WH; Seynaeve C; Schmitz PI; Stoter G
J Natl Cancer Inst; 1996 Oct; 88(19):1393-8. PubMed ID: 8827017
[TBL] [Abstract][Full Text] [Related]
16. Dosing regimen of granulocyte-macrophage colony-stimulating factor to support dose-intensive chemotherapy.
Neidhart JA; Mangalik A; Stidley CA; Tebich SL; Sarmiento LE; Pfile JE; Oette DH; Oldham FB
J Clin Oncol; 1992 Sep; 10(9):1460-9. PubMed ID: 1517789
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells.
Winter JN; Lazarus HM; Rademaker A; Villa M; Mangan C; Tallman M; Jahnke L; Gordon L; Newman S; Byrd K; Cooper BW; Horvath N; Crum E; Stadtmauer EA; Conklin E; Bauman A; Martin J; Goolsby C; Gerson SL; Bender J; O'Gorman M
J Clin Oncol; 1996 Jan; 14(1):277-86. PubMed ID: 8558209
[TBL] [Abstract][Full Text] [Related]
18. [Effect of granulocyte colony stimulating factor (G-CSF) on peripheral blood leukocytes and lymphocytes in patients with chemotherapy-induced leukopenia].
Böhme M; Schmidt D; Radke J; Morenz J; Weise W
Geburtshilfe Frauenheilkd; 1994 Dec; 54(12):670-4. PubMed ID: 7531660
[TBL] [Abstract][Full Text] [Related]
19. Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF.
Ballestrero A; Ferrando F; Garuti A; Basta P; Gonella R; Stura P; Mela GS; Sessarego M; Gobbi M; Patrone F
J Clin Oncol; 1999 Apr; 17(4):1296. PubMed ID: 10561192
[TBL] [Abstract][Full Text] [Related]
20. Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Medical Research Council Lung Cancer Working Party.
Thatcher N; Clark PI; Smith DB; Anderson H; Girling DJ; Machin D; Stephens RJ; Lallemand G; Jenkins B
Clin Oncol (R Coll Radiol); 1995; 7(5):293-9. PubMed ID: 8580054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
